- Emeritus Scientist, Cancer Control Research, BCCA
- Clinical Professor, School of Population and Public Health, UBC
- Associate Member, Dermatology, UBC
- Associate Member, Ophthalmology, UBC
- Associate Member, Surgery, UBC
- Fellow, American College of Epidemiology, 1992
- MA (Medical Sociology), Western Washigton University, 1973
- BSc (Biological Science), UBC, 1967
My principal interest is in the interaction of environmental factors and susceptibility genes in determining cancer risk, especially for cutaneous malignant melanoma, prostate cancer, non-Hodgkin lymphoma, and non-melanocytic skin cancers.
At the present time a number of studies are underway including investigations of the putative relationship between plasma organochlorine compounds and both melanoma and non-Hodgkin lymphoma. In collaboration with other members of the program we are conducting similar studies of multiple myeloma and other cancers. Investigations of prostate cancer are underway to see if factors associated with increased risk of developing the disease might also be associated with aggressive vs indolent disease.
Data from several of these investigations are part of large multi-national collaborative consortia including the Genes Environment and Melanoma (GEM) consortium and the InterLymph consortium. Aggregation of environmental and genetic data in these consortia enables large scale datasets to be assembled to test gene-environment interaction hypotheses, especially on tumours which are relatively rare in any single study.Our BC Generations Project www.bcgenerationsproject.ca is assembling a cohort of 40,000 British Columbia residents between the ages of 35 and 69, who complete an etiologic questionnaire and contribute blood and urine specimens for storage, and will be followed over the next 25 years to investigate gene - environment interaction in the causation of cancer and other chronic disease. Together with investigators in 4 other provinces also recruiting participants we expect to be able to build a research platform comprised of data and specimens from 300,000 Canadian called the Canadian Partnership for Tomorrow. The platform will allow large-scale studies of the causes of many chronic diseases, and facilitate identification of new early disease detection biomarkers, and markers of carcinogenic exposure by Canadian and international scientists for many years in the future.